CGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compugen Ltd (CGEN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has potential in its immuno-oncology pipeline and a positive analyst rating, the technical indicators and financial performance suggest caution. The stock's recent price trend is flat, and there are no significant trading signals or catalysts to justify immediate investment.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 35.291, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level of 2.045, with resistance at 2.297. Overall, the technical indicators do not suggest a strong buy signal.
Analyst initiated a Buy rating with a $4 price target, citing the company's immuno-oncology pipeline and potential royalty streams from AstraZeneca's peak sales estimates.
No recent news or significant trading activity from hedge funds, insiders, or Congress. Financial performance shows a significant drop in net income and EPS despite a sharp revenue increase.
In Q4 2025, revenue increased by 4477.29% YoY to $67.33M, but net income dropped by -1029.30% YoY to $56.85M, and EPS fell by -942.86% YoY to 0.59. Gross margin improved to 94.75%, up 75.11% YoY, indicating operational efficiency despite profitability challenges.
H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, citing the company's strong pipeline and potential royalty streams.
